IMNM Relative Valuation
IMNM's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, IMNM is overvalued; if below, it's undervalued.
Historical Valuation
Immunome Inc (IMNM) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.00 is considered Undervalued compared with the five-year average of -5.52. The fair price of Immunome Inc (IMNM) is between +Inf to +Inf according to relative valuation methord. Compared to the current price of 19.57 USD , Immunome Inc is Undervalued By Fair.
Relative Value
Fair Zone
+Inf-+Inf
Current Price：19.57
Fair
Undervalued
-8.13
PE
1Y
3Y
5Y
Trailing
Forward
-6.51
EV/EBITDA
Immunome Inc. (IMNM) has a current EV/EBITDA of -6.51. The 5-year average EV/EBITDA is -0.90. The thresholds are as follows: Strongly Undervalued below -4.20, Undervalued between -4.20 and -2.55, Fairly Valued between 0.75 and -2.55, Overvalued between 0.75 and 2.41, and Strongly Overvalued above 2.41. The current Forward EV/EBITDA of -6.51 falls within the Strongly Undervalued range.
-6.16
EV/EBIT
Immunome Inc. (IMNM) has a current EV/EBIT of -6.16. The 5-year average EV/EBIT is -3.49. The thresholds are as follows: Strongly Undervalued below -10.29, Undervalued between -10.29 and -6.89, Fairly Valued between -0.09 and -6.89, Overvalued between -0.09 and 3.31, and Strongly Overvalued above 3.31. The current Forward EV/EBIT of -6.16 falls within the Historic Trend Line -Fairly Valued range.
736.34
PS
Immunome Inc. (IMNM) has a current PS of 736.34. The 5-year average PS is 137.24. The thresholds are as follows: Strongly Undervalued below -469.83, Undervalued between -469.83 and -166.29, Fairly Valued between 440.78 and -166.29, Overvalued between 440.78 and 744.31, and Strongly Overvalued above 744.31. The current Forward PS of 736.34 falls within the Overvalued range.
-8.04
P/OCF
Immunome Inc. (IMNM) has a current P/OCF of -8.04. The 5-year average P/OCF is -3.84. The thresholds are as follows: Strongly Undervalued below -10.68, Undervalued between -10.68 and -7.26, Fairly Valued between -0.41 and -7.26, Overvalued between -0.41 and 3.01, and Strongly Overvalued above 3.01. The current Forward P/OCF of -8.04 falls within the Undervalued range.
-8.04
P/FCF
Immunome Inc. (IMNM) has a current P/FCF of -8.04. The 5-year average P/FCF is -3.69. The thresholds are as follows: Strongly Undervalued below -12.02, Undervalued between -12.02 and -7.85, Fairly Valued between 0.48 and -7.85, Overvalued between 0.48 and 4.65, and Strongly Overvalued above 4.65. The current Forward P/FCF of -8.04 falls within the Undervalued range.
Immunome Inc (IMNM) has a current Price-to-Book (P/B) ratio of 6.73. Compared to its 3-year average P/B ratio of 5.45 , the current P/B ratio is approximately 23.39% higher. Relative to its 5-year average P/B ratio of 4.58, the current P/B ratio is about 46.81% higher. Immunome Inc (IMNM) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -14.52%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -18.28% , the current FCF yield is about -100.00% lower.
6.98
P/B
Median3y
5.45
Median5y
4.58
-10.80
FCF Yield
Median3y
-14.52
Median5y
-18.28
Competitors Valuation Multiple
The average P/S ratio for IMNM's competitors is 3.16, providing a benchmark for relative valuation. Immunome Inc Corp (IMNM) exhibits a P/S ratio of , which is -100.00% above the industry average. Given its robust revenue growth of -100.00%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of IMNM increased by 89.17% over the past 1 year. The primary factor behind the change was an decrease in P/E Change from -2.72 to -7.15.
The secondary factor is the Margin Expansion, contributed 26.84%to the performance.
Overall, the performance of IMNM in the past 1 year is driven by P/E Change. Which is more unsustainable.
People Also Watch
FAQ
Is Immunome Inc (IMNM) currently overvalued or undervalued?
What is Immunome Inc (IMNM) fair value?
How does IMNM's valuation metrics compare to the industry average?
What is the current P/B ratio for Immunome Inc (IMNM) as of Dec 05 2025?
What is the current FCF Yield for Immunome Inc (IMNM) as of Dec 05 2025?
What is the current Forward P/E ratio for Immunome Inc (IMNM) as of Dec 05 2025?